GlaxoSmithKline said it would temporarily withdraw its application to expand use of Avodart--which is approved to treat symptoms of an enlarged prostate--to include cancer prevention. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.
